A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer and other tumor types has dosed the first patients in its dose expansion stage. Early results are expected later this year. Roughly 75 adults will be enrolled in this stage of the trial (NCT03364400). Besides ovarian cancer, the other groups will have patients with either pancreatic cancer, triple negative breast cancer, or glioblastoma — all of which express high levels…
April 23, 2020April 23, 2020